A flowchart describes the stepwise analysis of missense SNPs in the human PC and illustrates the computational tools used in the study. by Mahvash Farajzadeh-Dehkordi (17468232)

De-identified dataset. by Zeshan A. Chisty (18388200)

“…</p><p>Results</p><p>The median age of the 37 participants at enrollment was 70.5 years; 30 (81%) had prior SARS-CoV-2 infection, and 76% received Pfizer-BioNTech and 24% Moderna homologous vaccines. …”

Simultaneous imaging of cell shape, mitochondrial potential and nuclear modifications at the onset and during the various stages of apoptosis. by Frédérique Nolin (2151472)

“…Simultaneous time-lapse confocal imaging of cell shape (DIC), TMRE and H2B-GFP was performed by two-photon excitation every five minutes for 7 hours and 15 minutes after the induction of apoptosis by the addition of 500 ng/mL AMD. …”

cMSC/Collagen Type I gel fabrication. by Melissa A. MacIver (12850566)

ND5 mutant mitochondria have a reduced ability to buffer calcium. by Matthew McKenzie (849898)

“…Control (CON) cybrid mitochondria were able to buffer more calcium than both ND5 mutant cybrid mitochondria and ρ⁰ cell mitochondria. …”

Root phenotype of <i>ibr5</i> alleles compared to wild-type. by Kim L. Johnson (204164)

“…L<i>er</i> roots show a 55<b>%</b> decrease in root length when grown on 10 mM IAA compared to un-supplemented medium and <i>tink/ibr5-6</i> plants show a similar root inhibition phenotype (p value ≤ 0.3). …”

DN Rab5 (S34N) retards endocytosis of KCa2.3. by Yajuan Gao (309862)

“…</b> Expression of S34N Rab5 resulted in a significant decrease of KCa2.3 endocytosis, relative to WT Rab5 (<i>n</i> = 3; *P<0.05). …”

Superhydrophobic Modification of Atomic Layer Deposition Antireflection Aluminum Oxide Film: A Simple Evaporative Coating Technique by Zeyu An (19798137)

Influence of COS on the activation of NF-κB in retina and RGC-5 cells. by I-Mo Fang (470460)

“…(B) COS decreased the amount of activated NF-κB translocated into nucleus in PQ-stimulated RGC-5 in a time-dependent and (C) dose-dependent manner. …”

Adverse childhood experiences and chronic lung diseases in adulthood: a systematic review and meta-analysis by Samuel Lopes (8411688)

Depletion of Opa1 and Marf does not cause increase in the cleaved Caspase 3 levels and apoptosis in the brain. by Dnyanesh Dubal (12085942)

Analysis of proliferation in NBs depleted of Opa1 and Marf. by Dnyanesh Dubal (12085942)

Subgroup analysis. by Bruno Martins Tomazini (6509528)

“…</p><p>Results</p><p>From September 25, 2021, to February 3, 2022, 153 patients were randomized. The mean decay rate in SARS-CoV-2 viral load log₁₀ within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”

Study outcomes. by Bruno Martins Tomazini (6509528)

“…</p><p>Results</p><p>From September 25, 2021, to February 3, 2022, 153 patients were randomized. The mean decay rate in SARS-CoV-2 viral load log₁₀ within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”

Intranasal NIC-hLYS is efficacious in vivo against MERS-CoV. by Ashlee D. Brunaugh (4263472)

“…<p>The efficacy of NIC-hLYS particles was assessed in a lethal MERS-CoV infection model (A). Once daily intranasal administration of NIC-hLYS particles suspended in 0.45% sodium chloride resulted in 43% survival in a lethal MERS-CoV infection (B) and produced a statistically significant decrease in lung viral titer at the highest dose tested (C). …”

Intranasal NIC-hLYS is efficacious in vivo against MERS-CoV. by Ashlee D. Brunaugh (4263472)

“…<p>The efficacy of NIC-hLYS particles was assessed in a lethal SARS-CoV-2 infection model (A). Once daily intranasal administration of NIC-hLYS particles suspended in 0.45% sodium chloride resulted in 30% survival in a lethal SARS-CoV-2 infection (B) and produced a statistically significant decrease in lung viral titers after 10 days of dosing (C). …”

Histological abnormalities in E18.5 ATF2 mutant cerebellum and brainstem. by Julien Ackermann (223933)

“…Number of hypoglossal motoneurons (h) is bilaterally decreased in <i>Atf2^−/−</i> embryos while number of dorsal vagal motoneurons (v) appears normal. …”

Adverse events ^a. by Bruno Martins Tomazini (6509528)

“…</p><p>Results</p><p>From September 25, 2021, to February 3, 2022, 153 patients were randomized. The mean decay rate in SARS-CoV-2 viral load log₁₀ within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”

Rhinorrhea-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…</p><p>Results</p><p>From September 25, 2021, to February 3, 2022, 153 patients were randomized. The mean decay rate in SARS-CoV-2 viral load log₁₀ within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”

Vomit-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…</p><p>Results</p><p>From September 25, 2021, to February 3, 2022, 153 patients were randomized. The mean decay rate in SARS-CoV-2 viral load log₁₀ within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”